Merck is discussing the study data with regulators worldwide, with a goal of making the treatment available for infants as early as the 2025 to 2026 RSV season.

We recently compiled a list of the 10 High Growth Pharma Stocks That Are Profitable in 2025. Merck & Co., Inc. stands third among them. Merck & Co., Inc. (NYSE:MRK), a global leader in pharmaceuticals ...

(Reuters) -Merck's antibody-based shot met the main goal of a mid-to-late stage trial, when tested to protect infants against a disease caused by the respiratory syncytial virus (RSV), the company ...

Merck is discussing the study data with regulators worldwide, with a goal of making the treatment available for infants as early as the 2025 to 2026 RSV season.

Merck is discussing the study data with regulators worldwide, with a goal of making the treatment available for infants as early as the 2025 to 2026 RSV season.

Called Enflonsia and developed by Merck & Co., the drug is an antibody intended to prevent illness from RSV, which can be particularly severe in young children.

Merck's shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus, which was in short supply nationwide during the 2023 RSV season due to unprecedented ...

CDC panel backs Merck's Enflonsia for RSV prevention in infants; FDA-approved therapy reduced hospitalizations by 84% in clinical trials.

Pharmalittle: We’re reading about a Merck shot for RSV, a lawsuit over an Arkansas PBM law, and more Drugmakers met with Trump officials about lowering drug prices but no commitments were made ...

Merck is discussing the study data with regulators worldwide, with a goal of making the treatment available for infants as early as the 2025 to 2026 RSV season.